Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer

British Journal of Urology

Volumn 77, Issue 5, 1996, Pages 667-671

  Kriegmair, M ^a,b   Baumgartner, R ^a   Lumper, W ^a   Waidelich, R ^a   Hofstetter, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

5 Aminolevulinic acid; Photodynamic therapy; Superficial bladder cancer

Indexed keywords

AMINOLEVULINIC ACID; BCG VACCINE; BICARBONATE; MITOMYCIN C; PHOTOFRIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTECTOMY; DYE LASER; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; NEODYMIUM LASER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SUPERFICIAL CANCER;

EID: 0030422977     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.09717.x     Document Type: Article

References (23)

1. Proul GP, Lin C-W. Benson R et al. Photodynainic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. KnillJ Med 1987: 317: 1251-5
2. Nseyo CO, Crawford ED. Shumaker BP. Hoodin At). Marcus SL. Dugan MH. A phase II multicenter trial ol'photodynamic therapy as treatment for refractory carcinoma in situ. J U ml 1993: 149: 28IA
3. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Ural 1976: 115: 150-1
4. Kriegmair M. Waidelich R, Lumper W, Ehsan A, Baumgartner R. Hofstetter A. Integral photodynamic treatment of refractory superficial bladder cancer. J Llrol 1995; 154: 1359-41
5. Dougherty TJ. Cooper MT. Mang TS. Cutaneous phototoxic occurrences in patients receiving photofrin. Lasers Sura Med 1990: 10: 485-8
6. Harty Jl, Amin M, Wiemann TJ. Tseng MT, Ackerman D. Broghamer W. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Ural 1989: 141: 1 541-6
7. Kennedy JC. Pottier HI I. Endogenous protoporphyrin IX. a clinically useful photoscnsiti/er for photodynamic therapy. J Plwtocliem Photobiol K: Kiol 1992: 14: 275-92
8. Bedwell J. MacRoherI AJ. Phillips I). Bown SG. Fluorescence distribution and photodynamic effect of ALA-induced PPIX in the DMH rat colonie tumour model. Rr J Cancer 1992: 65: 818-24
9. Huland H. Klöppel G. Feddersen I et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective mullicenter study with 419 patients. J Urol 1990: 144: 68-72
10. Dougherty TJ. Marcus SL. Photodynamic therapy, Eur J Cancer 1992: 28: 1754-42
11. Baumgartner R. Fuchs N. Jocham D. Stepp II. Unsold K. Pharmacokinetics of fluorescent polyporphyrin pholofrin II in normal nit tissue und rat bladder tumor. I'hoioehem Photobiol 1992: SS: 569-74
12. Harty JI. Amin M. Wiemann TJ. Tseng MT. Ackcrman I), Broghamer W. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Ural 1989; 141: 1 341-6
13. Nseyo UO. Lundhal SL. Merrill DC. Whole bladder photodynamic therapy: Critical review of present-day technology and rationale for development of intravesical laser catheter and monitoring system. Urology 1990: 36: 398-402
14. U'Hallewin MA, Baert I,. Marijnissen PA. Star WM. Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder. J Urol 1992: 148: 1152-5
15. Kriegmair M. Baumgartner R. Knüchel R et al. Fluorescence detection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994: 44 : 836-41
16. Steinbach P. Kriegmair M. Baumgartner R. Hofstädter F, Knüchel R. Intravesical instillation of 5-aminoIcvulinic acid: The lluorescent metabolite is limited to urothelial cells. Urohcni 1994: 44: 676-81
17. Potter WR. Mang S. Dougherty TJ. The theory of photodynamic therapy dosimetry: Consequences of photodestruction of sensitizer. Plwtochcm Plwtobiul 1987: 46: 97-101
18. Nseyo UO. Photodynamic therapy. In Lamm Ul. eds. The Urologie Clinics of North American. 3rd edn. Vol. 19. Philadelphia: Saunders. 1992: 591-9
19. Wessels JM. Sroka R. Heil P. Seidlitz HK. Photodegradation of protoporphyrin-dimethylester in solution and in organized environments. Int J Radiât Rial 199 3: 64: 475-84
20. Goff BA. Bamberg M. Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cnneer Res 1991: 51: 4762-7
21. Kriegmair M. Baumgartner R. Stocker S. Riesenberg R. Hofstetter A. Knüchel R. Steinbach P. Photodynamic therapy of urothelial cancer following intravesical application of 5-aminolevulinic acid in a rat bladder tumormodel. J Urol 1994: 151: 518A
22. Van Gemert MJC. Cheong WF, Welch A. Star WM. Light delivery for whole-bladder photodynamic therapy. IMS in Med Seien 1987: 2: 273-84
23. Loh CS. Mac-Robert AJ, Bedwell f. Régula J. Krasner N. Bovvn SCî. Oral versus intravenous administration of 5-aminolevulinic acid for photodynamic therapy. Kr Cimcer 1993: 68: 41-51